Ordspono is a cancer medicine for treating adults with follicular lymphoma or diffuse large B-cell lymphoma (DLBCL), two types of blood cancer. Ordspono is used when the cancer has returned (relapsed) or not responded (refractory) after at least two previous therapies that affect the whole body (systemic therapies). Ordspono contains the active substance odronextamab.
Therapeutic Indication
### Therapeutic indication Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.
Therapeutic Area (MeSH)
ATC Code
Not yet assigned
ATC Item
xnot yet assigned
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Odronextamab | N/A | Odronextamab |
| odronextamab | N/A | Odronextamab |
EMA Name
Ordspono
Medicine Name
Ordspono
Aliases
N/ANo risk management plan link.
